Affimed Therapeutics (Germany)

Recent papers from Affimed Therapeutics (Germany)

1. VOGUE: Non-Inferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to TreatmentOpen Forum Infectious Diseases · 2026
2. Abstract 328: Establishment of assay systems for drug development against the oncogenic phosphatase WIP1.Cancer Research · 2026
3. An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trialNature Medicine · 2026
4. NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cellsOncoImmunology · 2026
5. CD16A Shedding Regulates Innate Cell Engager‐Induced Serial Killing by Natural Killer CellsEuropean Journal of Immunology · 2025
6. Improving a data mining based diagnostic support tool for rare diseases on the example of M. Fabry: Gender differences need to be taken into accountPLoS ONE · 2025
7. The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigmFrontiers in Immunology · 2025
8. IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screeningBlood · 2025
9. First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid TumorsClinical Cancer Research · 2025
10. A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell LymphomasClinical Cancer Research · 2024
11. Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).Journal of Clinical Oncology · 2024
12. Advancing the utilization of real‐world data and real‐world evidence in clinical pharmacology and translational research—Proceedings from the ASCPT 2023 preconference workshopClinical and Translational Science · 2024
13. Molecular characterization of chronic cutaneous wounds reveals subregion‐ and wound type‐specific differential gene expressionInternational Wound Journal · 2023
14. Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography methodmAbs · 2023
15. Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradicationScientific Reports · 2023
16. Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studiesTrials · 2023
17. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ LymphomaBlood · 2022
18. Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersTrends in Immunology · 2022
19. Design and conduct considerations for studies in patients with hepatic impairmentClinical and Translational Science · 2022
20. Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signalingFrontiers in Oncology · 2022